- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02065271
Herbal Preparation and Glucose Homeostasis (Herbie)
Rationale: The incidence of obesity and type 2 diabetes (T2D) is increasing rapidly and accounts for a considerable part of health care costs. Herbal supplements are used in many cultures for the prevention and treatment of many different conditions. Due to lack of scientific proof, the application in western cultures are minimal. Animal studies have shown that many constituents of such herbal supplements may have beneficial effects on several important parameters known to be affected in T2D. Still, no scientific proof in humans is available. We therefore aim to investigate the effect of 4-week herbal supplementation on glucose metabolism, lipid metabolism, vascular function and inflammation in subjects with increased fasting glucose levels or a decreased glucose tolerance.
Objective: The primary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on blood glucose levels and glucose tolerance. The secondary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, inflammation, adipose tissue and white blood cell gene-expression and AIX both fasted and during an OGTT test.
Study design: This study is a randomized, double-blind, placebo controlled cross-over trial in which two different treatments will be evaluated e.g. an intervention with the herbal mixture and a placebo. Each person will obtain both treatments in random order for four weeks with a wash out period of four weeks in-between. Fasting blood samples will be collected and subjects will receive a OGTT, paralleled by a PWA before and after 4-week supplementation.
Furthermore, after 4-week supplement intake we will collect a urine sample and collect an adipose tissue biopsy. The whole trial will last three months.
Study population: 26 overweight males and females 50-75yrs old with an increased fasting glucose or with an impaired glucose tolerance.
Intervention: Two intervention periods of 4-weeks in which participants will take three times a day a supplement of 500mg herbal or placebo.
Main study parameters/endpoints: Fasting blood glucose levels, glucose tolerance as determined by an oral glucose tolerance test (OGTT), AIX, triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, PWA, adipose tissue an white blood cell gene expression and markers of inflammation .
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects that will participate in the study will invest a total of 16.5 hours. Blood collection by vena punctures/insertion of the venflon and the collection of an adipose tissue biopsy can occasionally cause a local hematoma or bruise and some participants may report pain or discomfort. The herbal supplements contain small amounts St. John's wort, which may affect the function of liver enzymes. We will therefore monitor liver function parameters during the supplementation period. Furthermore, subjects are excluded if they use medication known to be affected by St. John's wort. Participant will donate 284ml of blood, dispersed over 12 weeks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Gelderland
-
Wageningen, Gelderland, Pays-Bas, 6703 HD
- Wageningen University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Males and postmenopausal females For females: menstrual cycle absent for more than 1 year
- age 50-70yrs
- BMI >27 kg/m2
- Increased fasting glucose or an impaired glucose tolerance (two-hour glucose levels >7.8 mmol/L on the 75-g oral glucose tolerance test or fasting glucose >6.1mmol/L).
Exclusion Criteria:
- Systolic blood pressure >160mmHg and diastolic blood pressure> 100mmHg
- Tobacco smoker
- Received inoculations within 2 months of starting the study or planned during the study
- Donated or intend to donate blood from 2 months before the study till months after the study.
- Unstable body weight (weight gain or loss >5kg in the past three months)
- Diagnosed with any long-term medical condition (e.g., diabetes, haemophilia, CVD, anemia, gastrointestinal disease, renal failure, thyroid disorders, cancer, HIV, hepatitis C)
- The use of the following medicine: medicine interfering with St Johns Worth such as, inhibitors of the immune system (ciclosporine, tacrolimus, everolimus, temsirolimus and sirolimus), coumarine type anticoagulant medicine (acenocoumarol and fenprocoumon), anti-epileptica (fenobarbital and fenytoïne), theophylline, atorvastatine, simvastatine, digoxine, kinidine, voriconazol, proton pump inhibitors (omeprazole and esomeprazole) and all anti-depressives ( incl. MAO inhibitors and SSRI's).
- Abuse of drugs/alcohol
- If the participant don't want to sign the informed consent
- If the participant don't want to be informed about unexpected findings during the screening or study
- Participation in another biomedical study
- Additional exclusion criteria for females:
Current use of contraceptives containing hormones Current use of hormone replacement therapy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: herbal supplements
500mg, 3 per day, 4weeks
|
|
|
Comparateur placebo: placebo
500mg, 3 per day, 4 weeks
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
change in glucose tolerance
Délai: baseline and after 4-week supplementation
|
by oral glucose tolerance test (OGTT)
|
baseline and after 4-week supplementation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
change in insulin
Délai: baseline and after 4-week supplementation
|
baseline and after 4-week supplementation
|
|
|
change in TAG
Délai: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
|
change in HbA1c
Délai: baseline and after 4 week supplementation
|
glycosylated haemoglobin
|
baseline and after 4 week supplementation
|
|
change in FFA
Délai: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
|
change in cholesterol
Délai: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
change in vascular function
Délai: baseline and after 4-week supplementation
|
by pulse wave analysis (PWA)
|
baseline and after 4-week supplementation
|
|
change in ALAT/ASAT
Délai: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
|
Urinary metabolites
Délai: after 4 week supplementation
|
after 4 week supplementation
|
|
|
adipose tissue gene expression
Délai: after 4 week supplementation
|
by qpcr
|
after 4 week supplementation
|
|
change in markers of inflammation
Délai: baseline and after 4 week of supplementation
|
by PBMC genexpression and plasma cytokines
|
baseline and after 4 week of supplementation
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Lydia A Afman, PhD, Wageningen University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NL44919.081.13
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur herbal supplement
-
Yao-Kuang WuRecrutement
-
Islamic Azad University, TehranComplétéGingiviteIran (République islamique d
-
Mclean HospitalNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Complété
-
Mclean HospitalNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RetiréFlux sanguin cérébral | Consommation d'alcool
-
Tata Memorial CentreRecrutementMucosite buccale (ulcéreuse)Inde
-
Tata Memorial CentreComplétéMucosite buccale (ulcéreuse)Inde